Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 135 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stable Coronary Heart Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

NCT03447990
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
Interventions
MYK-491, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Jacksonville, Florida • Saint Paul, Minnesota • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 2 Interventional

Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation

NCT06130059
View directory record Official record
Conditions
Heart Failure, Inflammation
Interventions
Low Dose Colchicine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)

NCT02575833
View directory record Official record
Conditions
Stable Angina
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available

Investigation of the Athero-Protective Effects of Clopidogrel

NCT01283282
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

NCT00642811
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel, Aspirin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Jonesboro, Arkansas • Ormond Beach, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Not applicable Interventional

Effects of Acupuncture on Symptoms of Stable Angina

NCT06311461
View directory record Official record
Conditions
Angina, Stable
Interventions
Acupuncture, Attention control
Procedure · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed No phase listed Observational

Does Lung Impedance Correlate With Changes in BNP in Stable and Acutely Decompensated Heart Failure Patients?

NCT00560339
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Southern New Jersey Cardiac Specialists
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
6
States / cities
Glendale, California • Voorhees Township, New Jersey • Roslyn, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2007 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Safety Study of Cenderitide in Stable Chronic Heart Failure

NCT02359227
View directory record Official record
Conditions
Heart Failure
Interventions
Cenderitide
Drug
Lead sponsor
Capricor Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

NCT01327846
View directory record Official record
Conditions
Atherosclerosis
Interventions
Canakinumab, Placebo, Standard of care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
315
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

NCT01103440
View directory record Official record
Conditions
Stable Angina
Interventions
Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities

NCT04572893
View directory record Official record
Conditions
Primary Familial Dilated Cardiomyopathy
Interventions
danicamtiv
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

NCT01814319
View directory record Official record
Conditions
Systolic Heart Failure
Interventions
Probenecid 1 gr oral twice daily, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 4 Interventional

Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study

NCT00343395
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AVANDAMET
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Not applicable Interventional

Breaking Fasts Ahead of Cardiac Caths

NCT06996639
View directory record Official record
Conditions
Stable Angina (SA), Unstable Angina (UA), NSTEMI - Non-ST Segment Elevation MI
Interventions
Non-Fasting, Fasting
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2 Interventional Results available

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

NCT03236311
View directory record Official record
Conditions
Microvascular Coronary Artery Disease
Interventions
SAR407899, Placebo, Adenosine, Regadenoson, 13N-ammonia, 82Rubidium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Los Angeles, California • Jacksonville, Florida • Wellington, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Readiness for Behavior Change After a Heart Attack

NCT01596036
View directory record Official record
Conditions
Myocardial Infarction, Stable Angina, Coronary Artery Disease
Interventions
Early appointment (within 10 days), Routine referral (at 5 weeks)
Behavioral · Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 13, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional

"ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

NCT00219011
View directory record Official record
Conditions
Heart Failure
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure

NCT00323037
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
carvedilol controlled release, carvedilol immediate release
Drug
Lead sponsor
CTI-1, LLC
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
75
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Ranolazine Among Unrevascularized Chronic Stable Angina Patients

NCT02265796
View directory record Official record
Conditions
Angina
Interventions
Ranolazine, Sugar pill
Drug
Lead sponsor
North Florida Foundation for Research and Education
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Recruiting Phase 3 Interventional

Outcome Research to Confirm the Anti-anginal Effect of T89 in Patients With Stable Angina

NCT03789552
View directory record Official record
Conditions
Chronic Stable Angina Pectoris
Interventions
T89 capsule, Placebo capsule
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional

Brief Behavioral Health Intervention Program for Patients With Stable Coronary Artery Disease

NCT03629158
View directory record Official record
Conditions
Coronary Artery Disease, Ischemic Heart Disease, Coronary Heart Disease
Interventions
CLIMB intervention
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
30 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional

Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease

NCT06342609
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Colchicine 0.5 MG
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Wave Crossover ECP Study for Simplified Therapy

NCT06571370
View directory record Official record
Conditions
Chronic Stable Angina, Refractory Angina
Interventions
External Counterpulsation
Device
Lead sponsor
Pression
Industry
Eligibility
35 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Monroe, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Evaluation of a Novel Non-Invasive Automated Fractional Flow Reserve Software System in Patients With Coronary Artery Disease

NCT06183294
View directory record Official record
Conditions
Stable Angina, Unstable Angina, NSTEMI
Interventions
Collecting invasive FFR measurements.
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 17, 2026, 4:09 AM EDT